Species: Human

Cell type: Fibrosarcoma

Transgenes: Firefly luciferase with neomycin resistance (Neo) for selection with G418 and enhanced green fluorescent protein (eGFP) with puromycin resistance (Puro) for selection with puromycin

Media: DMEM, 10% FBS, 1% Pen/Strep, 1.25 mg/mL G418, 1 μg/mL puromycin

Description: HT1080-Fluc-Neo/eGFP-Puro is a polyclonal population from the fibrosarcoma cell line HT1080 (ATCC® CCL-121™) transduced with a lentiviral vector LV-Fluc-P2A-Neo (LV011) encoding the firefly luciferase (Fluc) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the neomycin resistance gene (Neo) via a P2A cleavage peptide and LV-eGFP-PGK-Puro (LV031) encoding the enhanced green fluorescent protein (eGFP) cDNA under the spleen focus-forming virus (SFFV) promoter and the puromycin resistance gene (Puro) under the phosphoglycerate kinase promoter. 

The lentiviral vectors used are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).

Mycoplasma Testing:

HT1080-Fluc-Neo/eGFP-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

Cell Line Authentication:

The parental HT1080 cell line was authenticated are certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 9 STR loci including CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA and sex chromosome marker Amelogenin.

Recommended uses:

In vitro: This is a high firefly luciferase and eGFP expressing cell line suitable for use as a positive control cell line in bioluminescence and fluorescence assays to verify luciferase or eGFP expression respectively in your lentiviral transduced cells.

In vivo: HT1080 cells form tumors post implantation into immunosuppressed mice. In-life imaging for GFP fluorescence is not recommended due to high background autofluorescence. Tissues may be harvested post mortem for analysis by conventional fluorescence microscopy. 

For in vivo imaging, please use firefly luciferase or the nonimmunogenic NIS reporter gene for high resolution 3D SPECT or PET imaging.

References on NIS imaging:

1. Fruthwirth et al. A whole body dual modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment responses in different. microenvironments. J. Nucl. Med 2014. 55(4): 686-94.

2. Penheiter et al. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral and cell-based therapies. Curr Gene Ther. 2012, 12(1):33-47.

Publications that used associated reagents: 

LV-eGFP-PGK-Puro (LV031): Shen et al. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016. March 17: 127(11): 1449-58. 

Morphology: Low- and high-density cell morphology (200x)

Flow Cytometry for eGFP: HT1080-Fluc-Neo/eGFP-Puro (green) or control (HT1080-Fluc-Puro) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).

Luciferase Assay: 10⁴, 10⁵, or 10⁶ cells were placed in wells of a 96-well plate and 0.3 mg of D-luciferin was added to the indicated wells. The plate was immediately imaged using a Xenogen IVIS Spectrum.

Bioluminescent images showing growth of a subcutaneous HT1080-Fluc tumor in an athymic mouse

10⁷ HT1080-Fluc-Puro cells (Imanis Life catalog #CL076) were injected subcutaneously into the right flanks of female NCR athymic mice. Mice were imaged at day 0 on the day of cell implantation and subsequently at days 7 and 16 using a Perkin Elmer IVIS® Spectrum system, at 10-15 minutes post intraperitoneal injection of D-luciferin at 150 mg/kg. Tumor size was measured using calipers. Data from a representative mouse (ID#6329) is shown.